Analyst to hone in on Vyepti rollout and patient uptake in imminent Lundbeck report

The preventive migraine treatment, Vyepti, will likely be a key element of the Danish pharmaceutical firm’s upcoming second quarterly report on Wednesday.

Photo: Jens Dresling

The ongoing rollout of Lundbeck’s newest drug Vyepti, which is a migraine prevention treatment, will steal the show when the Danish pharmaceutical company publishes its second quarterly report on Wednesday, according to Sydbank analyst Søren Løntoft Hansen.

However, a great deal of tension for the upcoming report was released last week when Lundbeck upgraded its full-year 2022 guidance. The company explained the revised financial figures citing a strong US dollar and strong underlying positive momentum for its four key medicines.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs